Dynavax Technologies Corp.
Vaccine company reports on year of "achievement, maturation, and validation"
Published in Pharma Investments, Ventures and Law Weekly, March 20th, 2005
The company's financial results reflect an increase in clinical-development activity as phase II/III programs in ragweed allergy immunotherapy and in hepatitis B prophylaxis advanced, as well as activity related to earlier-stage preclinical programs, which are in line with the company's goals and expectations.
As of December 31, 2004, Dynavax reported that cash, cash equivalents, and marketable securities totaled $65.8 million compared to $71.5 million at September 30, 2004 and $29.1 million at December 31, 2003. The increase in cash from 2003 to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- AEterna Zentaris, Inc.
AEterna Zentaris subsidiary files preliminary prospectus for IPO - Accentia Biopharmaceuticals, Inc.
Biopharmaceutical company reports plans for initial public offering - Adenosine Therapeutics, LLC
Grant awarded for development of Parkinson disease treatment - Advanced Neuromodulation Systems, Inc.
Medical device firm reports 26% increase in fourth quarter revenue - Advanced Nutraceuticals, Inc.
Nutraceutical company reports income of $0.08 per share - Alkermes, Inc.
Pharmaceutical firm reports loss of $0.10 per share - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
